Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials
In this study, GLP-1RAs were associated with cardiovascular, renal, and metabolic benefits in type 2 diabetes without increasing cancer risk, though gastrointestinal adverse events were common. Our findings support the clinical use of GLP-1RAs, with attention to individual risk profiles and treatment tolerability.
Authors
- Ho Geol Woo (ORCID: https://orcid.org/0000-0001-6489-0100)
- Sang Youl Rhee (ORCID: https://orcid.org/0000-0003-0119-5818)
- Damien Yeo (ORCID: https://orcid.org/0000-0002-8601-7000)
- Dong Keon Yon (ORCID: https://orcid.org/0000-0003-1628-9948)
- Yong Suk Jo (ORCID: https://orcid.org/0000-0002-6422-6530)
- Jin Young Jeong (ORCID: https://orcid.org/0000-0002-8670-7036)
- Sunyoung Kim (ORCID: https://orcid.org/0000-0002-1736-9088)
- Yejun Son
- Yi Deun Jeong
Institutions
- Kyung Hee University (KR)
- Kyung Hee University Medical Center (KR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1111/dom.70298
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Iran Telecommunication Research Center
- Ministry of Science and ICT, South Korea
- Institute for Information and Communications Technology Promotion